MENU
APR 02, 2020 10:00 AM PDT

SARS-CoV-2 (CoVID-19: Emergence, Biology, and Countermeasures)

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Director, Division of Infectious Diseases, Craig-Weaver Professor of Pediatrics, Professor of Pathology, Microbiology & Immunology, Professor at Vanderbilt University
    Biography
      Mark Denison M.D. is the Craig-Weaver Professor of Pediatrics, Pathology, Microbiology & Immunology at Vanderbilt University Medical Center in Nashville, TN. Dr. Denison has performed over 25 years of NIH-funded research focused on the replication, pathogenesis, and evolution of coronaviruses, a family of RNA viruses from which SARS-CoV emerged. Coronaviruses cause respiratory infections in humans and increasingly are thought to be ubiquitous among mammalian species. Notably, a large number of novel coronaviruses have been identified in bats, suggesting that bats may be critical for the emergence of coronaviruses in other species. Coronaviruses may have unique potential for cross-species movement. They encode novel RNA synthesis and probable RNA proofreading functions, thereby conferring the ability to maintain large and complex genomes and to respond to host or other environmental changes. The Denison lab focuses on determining the mechanisms of coronavirus evolution and host species movement and adaptation, using synthetic biology and reverse genetics. Dr. Denison has served on the steering committee for the Southeast Regional Center of Excellence in Emerging Infections and Biodefense for the past eight years. In addition, he is the Chair of the Vanderbilt Institutional Biosafety Committee and has served on multiple Government and international panels involved in review or consideration of biodefense, biosecurity, and synthetic biology.

    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    DEC 03, 2020 4:30 PM PST
    C.E. CREDITS
    DEC 03, 2020 4:30 PM PST
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    JUL 22, 2020 10:00 AM PDT
    C.E. CREDITS
    JUL 22, 2020 10:00 AM PDT
    DATE: July 23, 2020 TIME: 10:00 am PDT The SARS-CoV-2 pandemic has taken a toll on many sectors of the medical community. As the pandemic took a grip on the laboratory, the need for diagnost...
    DEC 15, 2020 10:00 AM PST
    C.E. CREDITS
    DEC 15, 2020 10:00 AM PST
    DATE: December 15, 2020 TIME: 10:00am PST Scientists from Thermo Fisher Scientific will walk us through the world of microorganisms. They will discuss their most recent research on viruses,...
    AUG 25, 2020 8:00 AM PDT
    C.E. CREDITS
    AUG 25, 2020 8:00 AM PDT
    DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
    JAN 21, 2021 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    JAN 21, 2021 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: January 21, 2021 Time: 8:00am (PST), 11:00am (EST) Today, critical reagent characterization is a key component in the overall workflow to establish robust ligand binding assays (e.g.,...
    Loading Comments...
    Show Resources
    Attendees
    • See more